A modified COMS plaque for iris melanoma
نویسندگان
چکیده
Melanoma of the iris is a rare condition compared to posterior ocular tumors and in this case report we present a 51-year-old female patient with diffuse iris melanoma. Traditional COMS (Collaborative Ocular Melanoma Study) plaques are used at our institution for radiation therapy, so a novel modification of the traditional plaque was required to allow better conformance with placement on the cornea. The usual silastic insert was machined to dimensions in compliance with the cornea, placed without incident, and treatment delivered with excellent patient tolerance of the modified plaque.
منابع مشابه
Iris melanoma.
The iris is the least common site of primary uveal melanoma. The prognosis of iris melanoma is better than that of melanoma of the ciliary body and choroid, but the reason for this difference is unclear. One possible explanation is that iris melanoma is smaller than its posterior segment counterparts at the time of diagnosis. Most iris melanomas are spindle cell types, according to a modified C...
متن کاملSilastic Thickness Optimization in Uveal Melanoma Brachytherapy by Monte Carlo Method
Introduction In order to treat uveal Melanoma , first, radioactive seeds are laid on a silicone- made substance which is called Silastic after that they are inserted in the plaque, and finally, this plaque containing silicone-made substance is stitched to the sclera surface. The dose gradient within the tumor and healthy tissues can be varied due to changing the Silastic thickness between scler...
متن کاملDosimetric benefit of a new ophthalmic radiation plaque.
PURPOSE To determine whether the computed dosimetry of a new ophthalmic plaque, EP917, when compared with the standard Collaborative Ocular Melanoma Study (COMS) plaques, could reduce radiation exposure to vision critical structures of the eye. METHODS AND MATERIALS One hundred consecutive patients with uveal melanoma treated with COMS radiation plaques between 2007 and 2010 were included in ...
متن کاملImproved treatment planning for COMS eye plaques.
PURPOSE A recent reanalysis of the Collaborative Ocular Melanoma Study (COMS) medium tumor trial concluded that incorporating factors to account for anisotropy, line source approximation, the gold plaque, and attenuation in the Silastic seed carrier into the dose calculations resulted in a significant and consistent reduction of calculated doses to structures of interest within the eye. The aut...
متن کاملUveal Melanoma Research and Treatment at Mayo Clinic
Mayo Clinic in Rochester, Minnesota, has a long history in the treatment of uveal melanomas. In the early 1980s, Dennis Robertson, MD, was one of the first to use iodine-125 plaques, the form of brachytherapy most commonly used for treatment of uveal melanomas in the United States today. The plaques used in the Collaborative Ocular Melanoma Study (COMS), a multicenter study initiated in 1985 to...
متن کامل